Avanir Pharmaceuticals, Inc.
is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders.

Press Releases

AVANIR Pharmaceuticals Announces U.S. Launch and Availability of ONZETRA™ Xsail™ for the Acute Treatment of Migraine in Adults
May 16, 2016
Avanir Pharmaceuticals to Present Data on NUEDEXTA® and ONZETRA™ Xsail™ at American Academy of Neurology (AAN) 2016 Annual Meeting
Apr 15, 2016
Avanir Pharmaceuticals Announces FDA Approval of ONZETRA™ Xsail™ (AVP-825) for the Acute Treatment of Migraine in Adults
Jan 28, 2016
Divider